(PharmaNewsWire.Com, December 18, 2017 ) The North America mycoplasma testing market was worth USD 148.8 Million in 2016 and is estimated to be growing at a CAGR of 11.5%, to reach USD 256.5 Million by 2021. Mycoplasmas are small bacteria which do not possess a cell wall and they are one of the most prevailing sources of contamination of cell lines. Mycoplasma contamination is a major hurdle for a cell culturist. They are not visible in normal microscopes and their contamination does not alter pH or turbidity significantly.
Mycoplasma infections can be very severe. Mycoplasma contamination occurs if already infected culture is brought into the laboratory or a person with human mycoplasma enters the laboratory. Mycoplasma contamination is a severe problem because they can bring changes in cell culture such as altering cell metabolism, changes in chromosomes of cell culture. Hence, mycoplasma testing is regularly conducted in cell culture research laboratories.
Increase in investments in R&D in the field of life sciences, government organizations funding researchers in drug discovery and development, increase in the number of pharmaceutical and biotechnology industries are some of the major factors driving the growth of mycoplasma testing market in North America. Stringent government regulations and high costs involved with the mycoplasma testing methods are restraining the market growth.
Product • Kits & Reagent • Instruments • Services • Y-o-Y Growth Analysis, By Product • Market Attractiveness Analysis, By Product • Market Share Analysis, By Product
Technique • PCR • ELSA • Direct Assays • Indirect Assays • Microbial culture techniques • Enzymatic Methods • DNA Staining • Y-o-Y Growth Analysis, By Technique • Market Attractiveness Analysis, By Technique • Market Share Analysis, By Technique
Application • Cell Line Testing • Virus Testing • End-Of-Production Cell Testing • Other Applications • Y-o-Y Growth Analysis, By Application • Market Attractiveness Analysis, By Application • Market Share Analysis, By Application
End User • Pharmaceutical Companies • Contract Research Organizations • Academic Research Institutes • Cell Banks • Y-o-Y Growth Analysis, By End User • Market Attractiveness Analysis, By End User • Market Share Analysis, By End User
Based on region, North America mycoplasma testing market is segmented into USA and Canada. USA dominates the market in this region with many deep rooted pharmaceutical and biotechnology companies established and increase in cell culture research.
Some of the major companies in the mycoplasma testing market include PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, Biological Industries Israel Beit Haemek Ltd., and WuXi AppTec
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
